

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Aventis Pharma S.A.	12/22/2006

RECEIVING PARTY DATA

Name:	Pfizer Enterprises SARL
Street Address:	Rond Point Kirchberg
City:	51 Avenue J.F. Kennedy
State/Country:	LUXEMBOURG
Postal Code:	L-1855

PROPERTY NUMBERS Total: 19

Property Type	Number
Application Number:	60185378
Application Number:	60208938
Application Number:	09793520
Application Number:	10032489
Application Number:	10245500
Application Number:	60131678
Application Number:	09559737
Application Number:	10124458
Application Number:	10875019
Application Number:	09984043
Application Number:	09799615
Application Number:	09762092
Application Number:	09744547
Application Number:	09951505
Application Number:	60190061

PATENT

500227010

REEL: 018915 FRAME: 0183

CH \$760.00 60185378

Application Number:	09809329
PCT Number:	EP0102723
PCT Number:	EP0004178
PCT Number:	EP0103500

CORRESPONDENCE DATA

Fax Number: (860)441-5082
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 860.441.4957
 Email: jackie.groton.lawrence@pfizer.com
 Correspondent Name: Jackie Lawrence
 Address Line 1: Eastern Point Road
 Address Line 2: Mailstop 8260-1615
 Address Line 4: Groton, CONNECTICUT 06340

ATTORNEY DOCKET NUMBER:	PC22100-22107
-------------------------	---------------

NAME OF SUBMITTER:	JLawr
--------------------	-------

Total Attachments: 7
 source=Scan001#page1.tif
 source=Scan001#page2.tif
 source=Scan001#page3.tif
 source=Scan001#page4.tif
 source=Scan001#page5.tif
 source=Scan001#page6.tif
 source=Scan001#page7.tif

**Stage 2 (Non-Pfizer Territory Countries)
General Assignment for Non-Pfizer Territories**

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, **AVENTIS PHARMA S.A.**, a corporation organized and existing under the laws of France of **20, AVENUE RAYMOND ARON, 92160 ANTONY, FRANCE** hereby sell, assign and transfer unto **PFIZER ENTERPRISES SARL** a Luxembourg Company having a place of business at **ROND POINT KIRCHBERG 51 AVENUE J.F. KENNEDY L-1855, LUXEMBOURG** the entire right, including priority rights, title and interest if applicable in the following patent families identified below by PC reference number and named as:

PC22100 entitled “**COMPOSITION AND METHOD COMPRISING CPT-11 AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER**”;

PC22101 entitled “**METHOD FOR TREATING CANCER USING CAMPTOTHECIN DERIVATIVES AND 5-FLUOROURACIL**”;

PC22102 entitled “**COMBINATION COMPRISING CAMPTOTHECIN AND A STILBENE DERIVATIVE FOR THE TREATMENT OF CANCER**”;

PC22103 entitled “**A COMPOSITION COMPRISING CAMPTOTHECIN OR A CAMPTOTHECIN DERIVATIVE AND AN ALKYLATING AGENT FOR THE TREATMENT OF CANCER**”;

PC22104 entitled “**USE OF CAMPTOTHECIN DERIVATIVES WITH REDUCED GASTROINTESTINAL TOXICITY**”;

PC22105 entitled “**PREPARATION OF CAMPTOTHECIN AND NOTHAPODYTINE DERIVATIVES**”;

PC22106 entitled “**METHOD FOR PREPARING CAMPTOTHECIN AND ITS DERIVATIVES**”; and

**Stage 2 (Non-Pfizer Territory Countries)
General Assignment for Non-Pfizer Territories**

PAGE 2 OF 3

PC22107 entitled "COMPOSITION COMPRISING CAMPTOTHECIN OR A CAMPTOTHECIN DERIVATIVE AND A TOPOISOMERASE II INHIBITOR FOR THE TREATMENT OF CANCER";


and detailed county list in the attached Appendix 1, and any associated family members not herein identified in Appendix 1, in non-Pfizer Territory wherein said Pfizer Territory is defined as the United States of America, it's territories and possessions, Canada, Mexico, Latin America, Australia, New Zealand and non-French speaking countries of the Caribbean (Trinidad, Tobago, Barbados, Netherlands Antilles, including Curacao, Aruba, St. Marteen and Bonaire, Antigua, St. Lucia, Dominica, St. Kitts, Anguila, Jamaica, Cayman Islands, the Dominican Republic and the Bahamas) for Letters Patent for any or all of said inventions and we hereby agree, whenever requested, to communicate to said **PFIZER ENTERPRISES SARL** and their successors and assigns, any facts known to Aventis Pharma Inc. respecting said inventions, to have an representative of Aventis Pharma Inc. to testify, if requested, in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the non-Pfizer Territories.

Signed and witnessed this _____ day of 22 DEC. 2006 at ANTONY



**Magalie Le Pennec, Attorney
For Aventis Pharma S.A.**

In the presence of:



(Typed or Printed Name of Witness)

**Josiane MERLIER
Director, Patent Administration**

AVENTIS PHARMA S.A.
20 avenue Raymond Aron
92160 ANTONY - France
R.C.S. Nanterre B 304 463 284

Stage 2 (Non-Pfizer Territory Countries)
General Assignment for Non-Pfizer Territories

PAGE 3 OF 3

HEREBY ACCEPTED ON BEHALF OF PFIZER ENTERPRISES SARL

Signed and witnessed this


6

day of

February 2007

at

Luxembourg


Louis Meert
Authorized Signor

In the presence of


Christophe Plantegeaet
(Typed or Printed Name of Witness)

Attachment: Appendix 1 Family Lists For PC22100 to PC22107

Docket Number Former Dkt No. Country Application Number
COMPOSITION AND METHOD COMPRISING CPT-11 AND A PYRIMIDINE DERIVATIVE FOR THE
TREATMENT OF CANCER

22100	ST:00016	United States	60/185378
22100	ST:00016	United States	60/208938
022100A	ST:00016	Australia	60111/01
022100A	ST:00016	Brazil	PI0108728-2
022100A	ST:00016	Canada	2401191
022100A	ST:00016	China P.R.	1805704.7
022100A	ST:00016	Czech Republic	2002-2892
022100A	ST:00016	European Patent Convention	1933683.3
022100A	ST:00016	Estonia	P200200471
022100A	ST:00016	Hungary	P0300848
022100A	ST:00016	Israel	150953
022100A	ST:00016	Japan	2001-561302
022100A	ST:00016	Norway	20024076
022100A	ST:00016	Patent Cooperation Treaty	PCT/EP01/02723
022100A	ST:00016	Slovak Republic	1224-2002
022100A	ST:00016	United States	09/793520
022100B	ST:00016	United States	10/032489
022100C	ST:00016	United States	10/245500
022100A	ST:00016	Singapore	200204648-0
022100A	ST:00016	Croatia	P20020658A
022100A	ST:00016	Bosnia-Herzegovina	BAP021181A
022100A	ST:00016	Serbia-Montenegro	P-646-02
022100A	ST:00016	South Africa	2002/6864
022100A	ST:00016	New Zealand	520593
022100A	ST:00016	Eurasian Patent Convention	200200922
022100A	ST:00016	Poland	P363110
022100A	ST:00016	Taiwan	90104504
022100A	ST:00016	India	2002/00749/DEL
022100A	ST:00016	Indonesia	W-00200201934
022100A	ST:00016	Korea South	7011248/2002
022100A	ST:00016	Mexico	PA/a/2002/008355
022100A	ST:00016	Armenia	200200922
022100A	ST:00016	Azerbaijan	200200922
022100A	ST:00016	Belarus	200200922
022100A	ST:00016	Kazakhstan	200200922
022100A	ST:00016	Kyrgyzstan	200200922
022100A	ST:00016	Moldova	200200922
022100A	ST:00016	Russian Federation	200200922
022100A	ST:00016	Tajikistan	200200922
022100A	ST:00016	Turkmenistan	200200922
022100A	ST:00016	Hungary	P0500729

METHOD FOR TREATING CANCER USING CAMPTOTHECIN DERIVATIVES AND 5-FLUOROURACIL

022101A	ST:99013	United States	60/131678
022101A	ST:99013	United States	09/559737
022101A	ST:99013	Australia	45642/00
022101A	ST:99013	European Patent Convention	927178.4
022101A	ST:99013	Patent Cooperation Treaty	PCT/EP00/04178
022101A	ST:99013	Japan	566630/01
022101B	ST:99013	United States	10/124458
022101C	ST:99013	United States	10/875019

COMBINATION COMPRISING CAMPTOTHECIN AND A STILBENE DERIVATIVE
FOR THE TREATMENT OF CANCER

022102A	ST:00035	Serbia-Montenegro	P-298/03
022102A	ST:00035	Bosnia-Herzegovina	BAP031376A
022102A	ST:00035	Brazil	PI0114856-7
022102A	ST:00035	Canada	2426898
022102A	ST:00035	Eurasian Patent Convention	200300516
022102A	ST:00035	Armenia	200300516
022102A	ST:00035	Azerbaijan	200300516

022102A	ST:00035	Belarus	200300516
022102A	ST:00035	Kazakhstan	200300516
022102A	ST:00035	Kyrgyzstan	200300516
022102A	ST:00035	Moldova	200300516
022102A	ST:00035	Russian Federation	200300516
022102A	ST:00035	Tajikistan	200300516
022102A	ST:00035	Turkmenistan	200300516
022102A	ST:00035	China P.R.	1817980
022102A	ST:00035	South Africa	2003/2552
022102A	ST:00035	New Zealand	524855
022102A	ST:00035	Estonia	P200300184
022102A	ST:00035	Norway	20031656
022102A	ST:00035	European Patent Convention	1988584.7
022102A	ST:00035	Australia	2002216029
022102A	ST:00035	United States	09/984043
022102A	ST:00035	Hong Kong	4101397.3
022102A	ST:00035	Colombia	3032010
022102A	ST:00035	Mexico	PA/a/2003/002882
022102A	ST:00035	Israel	155509
022102A	ST:00035	Philippines	1-2003-500138
022102A	ST:00035	Indonesia	W-00200300819
022102A	ST:00035	Czech Republic	PV 2003-1168
022102A	ST:00035	Slovak Republic	PP 512-2003
022102A	ST:00035	Singapore	200301692-0
022102A	ST:00035	Poland	P365685
022102A	ST:00035	Bulgaria	107806
022102A	ST:00035	Korea South	10-2003-7005754
022102A	ST:00035	Croatia	P20030382A
022102A	ST:00035	India	594/CHENP/2003
022102A	ST:00035	Hungary	P0302629
022102A	ST:00035	Japan	2002-537298

A COMPOSITION COMPRISING CAMPTOTHECIN OR A CAMPTOTHECIN DERIVATIVE
AND AN ALKYLATING AGENT FOR THE TREATMENT OF CANCER

022103A	ST:00013		60/190007
022103A	ST:00013	Australia	52235/01
022103A	ST:00013	European Patent Convention	1925510.8
022103A	ST:00013	United States	09/799615
022103A	ST:00013	Argentina	P010101256
022103A	ST:00013	Japan	2001-566630
022103A	ST:00013	Patent Cooperation Treaty	PCT/EP01/03500
022103A	ST:00013	Taiwan	90106304
022103B	ST:00013	United States	

USE OF CAMPTOTHECIN DERIVATIVES WITH REDUCED GASTROINTESTINAL TOXICITY

022104A	ST:98025	France	98 10043
022104A	ST:98025	Canada	2340020
022104A	ST:98025	China P.R.	99808836
022104A	ST:98025	Brazil	PI9912765
022104A	ST:98025	Turkey	2001/00331
022104A	ST:98025	United Arab Emirates	P27/2001
022104A	ST:98025	Serbia-Montenegro	P-53/2001
022104A	ST:98025	Korea North	PV 2001-382
022104A	ST:98025	Vietnam	1-2001-00107
022104A	ST:98025	Romania	99936674.3
022104A	ST:98025	Belarus	200100214
022104A	ST:98025	Kazakhstan	200100214
022104A	ST:98025	Tajikistan	200100214
022104A	ST:98025	Eurasian Patent Convention	200100214
022104A	ST:98025	Moldova	200100214
022104A	ST:98025	Armenia	200100214
022104A	ST:98025	Azerbaijan	200100214
022104A	ST:98025	Kyrgyzstan	200100214
022104A	ST:98025	Turkmenistan	200100214
022104A	ST:98025	Russian Federation	200100214
022104A	ST:98025	Great Britain	99936674.3
022104A	ST:98025	Slovenia	99936674.3
022104A	ST:98025	Portugal	99936674.3
022104A	ST:98025	Lithuania	99936674.3
022104A	ST:98025	Cyprus	99936674.3
022104A	ST:98025	Albania	99936674.3
022104A	ST:98025	Singapore	200100780.6
022104A	ST:98025	South Africa	2001/0839
022104A	ST:98025	Georgia	AP1999004240
022104A	ST:98025	Estonia	200100066
022104A	ST:98025	Australia	51687/99
022104A	ST:98025	Norway	200010454
022104A	ST:98025	Austria	EP1102594
022104A	ST:98025	Ireland	99936674.3
022104A	ST:98025	France	99936674.3
022104A	ST:98025	Italy	99936674.3
022104A	ST:98025	Denmark	99936674.3
022104A	ST:98025	Finland	99936674.3
022104A	ST:98025	Netherlands	99936674.3
022104A	ST:98025	Switzerland	99936674.3
022104A	ST:98025	Greece	99936674.3
022104A	ST:98025	Latvia	99936674.3
022104A	ST:98025	Spain	EP1102594
022104A	ST:98025	Luxembourg	99936674.3
022104A	ST:98025	Sweden	99936674.3
022104A	ST:98025	Monaco	99936674.3
022104A	ST:98025	Belgium	99936674.3
022104A	ST:98025	Germany	EP1102594
022104A	ST:98025	Sri Lanka	12332
022104A	ST:98025	United States	09/762092

022104A	ST:98025	New Zealand	509859
022104A	ST:98025	Mexico	PA/a/2001/000689
022104A	ST:98025	Czech Republic	PV2001-382
022104A	ST:98025	Japan	2000-563290
022104A	ST:98025	Hungary	103314
022104A	ST:98025	Bulgaria	105216
022104A	ST:98025	Slovak Republic	173-2001
022104A	ST:98025	Israel	141232
022104A	ST:98025	Poland	P345826
022104A	ST:98025	Indonesia	20010273
022104A	ST:98025	Korea South	7001471/2001
022104A	ST:98025	Ukraine	2001020806/M
022104A	ST:98025	Uzbekistan	IAP 20010167
022104A	ST:98025	India	00077/DEL
022104A	ST:98025	European Patent Convention	99936674.3

PREPARATION OF CAMPTOTHECIN AND NOTHAPODYTINE DERIVATIVES

022105A	ST:99017	France	99 06757
022105A	ST:99017	China P.R.	801114.1
022105A	ST:99017	Australia	49317/00
022105A	ST:99017	Canada	2340012
022105A	ST:99017	Great Britain	931353.7
022105A	ST:99017	Albania	931353.7
022105A	ST:99017	Cyprus	931353.7
022105A	ST:99017	Macedonia	931353.7
022105A	ST:99017	Lithuania	931353.7
022105A	ST:99017	Portugal	931353.7
022105A	ST:99017	Slovenia	931353.7
022105A	ST:99017	Netherlands	931353.7
022105A	ST:99017	Austria	EP1100799
022105A	ST:99017	Spain	EP1100799
022105A	ST:99017	Italy	931353.7
022105A	ST:99017	Belgium	931353.7
022105A	ST:99017	Finland	931353.7
022105A	ST:99017	France	931353.7
022105A	ST:99017	Luxembourg	931353.7
022105A	ST:99017	Greece	931353.7
022105A	ST:99017	Ireland	931353.7
022105A	ST:99017	Sweden	931353.7
022105A	ST:99017	Denmark	931353.7
022105A	ST:99017	Switzerland	931353.7
022105A	ST:99017	Germany	EP1100799
022105A	ST:99017	Latvia	931353.7
022105A	ST:99017	United States	09/744547
022105A	ST:99017	Japan	2001-500630
022105A	ST:99017	India	2001/00129
022105A	ST:99017	Mexico	PA/a/2001/000767
022105A	ST:99017	European Patent Convention	931353.7

METHOD FOR PREPARING CAMPTOTHECIN AND ITS DERIVATIVES

022106A	ST:00027	France	00 11769
022106A	ST:00027	United States	09/951505
022106A	ST:00027	Australia	93/90701

COMPOSITION COMPRISING CAMPTOTHECIN OR A CAMPTOTHECIN DERIVATIVE AND A TOPOISOMERASE II INHIBITOR FOR THE TREATMENT OF CANCER

22107	ST:00012	United States	60/190061
022107A	ST:00012	United States	09/809329